FIELD-LAB is a drug discovery facility that will help you to speed up the development and market launch of new nuclear drugs for cancer treatment. Through supply of small batches of radio chemicals and radio pharmaceuticals, we meet the need of Bio Pharma scientists and start-up ventures for research materials. This will drive both their ambitions to develop a new drug.
FIELD-LAB is part of a unique and complete nuclear infrastructure.
Read more about Nuclear Infrastructure
Currently, research is done on the production and development of various isotopes:
Learn more about FIELD-LAB and its importance. Discover our global network for pre-clinical and clinical research: research that is part of the development of every new medical product.
FIELD-LAB is created for and together with partners from different backgrounds. Some of the finest Dutch and British UMC’s have committed themselves to be part of this initiative. They believe in the beneficial results that will be brought to the Nuclear Medicine society. In addition, the partnerships that arise from FIELD-LAB form a portal to a fast growing network, which results in an open innovation environment.
Already in 2001, NRG supported the development of Peptide Receptor Radionuclide Therapy with carrier added Lutetium-177 (Lu-177 c.a.) by the supply of Lutetium-177 trichloride as a radiochemical. Nowadays, Lu-177 no carrier added is preferably used. “Lu-177 n.c.a. has a higher specific activity and thus radiolabeling efficiency, than lu-177 c.a.”, according to Marion Chomet, lead scientist at FIELD-LAB. Chomet and her colleagues are now fine-tuning and finalizing their custom made lutetium-177 n.c.a. process. But there are several challenges and practical considerations that they are facing.
The major bottleneck for research and development of radiopharmaceuticals for targeted alpha therapy is its limited availability. The irradiation of radium-226 could be a game changer as the amounts produced using this method could fulfill the market needs for alpha-emitters. However, there are several challenges in 226Ra target preparation and further processing of irradiated targets.
Karlijn van der Schilden
R&D Manager Medical Isotopes
T. +31 224 56 8018
T. +31 224 56 4196